Clinical trials
SMA clinical trials
Below are recruiting sma clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321977Recruiting
Walking test with a portable device for neuromuscular disease
This study tests a portable device that analyzes walking without markers. It aims to see if it can help assess walking in people with neuromuscular diseases and healthy volunteers, which could lead to simpler check-ups.
ParisAges 18–65 - NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT07286565Recruiting
Remote motor development study for early-diagnosed DMD or SMA
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
LiègeAges 4 months+ - NCT07221669RecruitingPhase 3
Pre-symptomatic salanersen study for babies with SMA
This trial tests if the drug salanersen can help movement and is safe when given to babies diagnosed with spinal muscular atrophy before they show symptoms. It's for very young infants with specific genetic types of SMA.
Chicago, IllinoisAges birth–1 month - NCT07072676Enrolling by invitation
Can a walker help prevent falls in neuromuscular disease?
This study tests if using assistive walking devices, after a short training period, can lower the risk of falls in people with neuromuscular diseases. It aims to help you stay steady and safe on your feet.
Bad FeilnbachAges 65–65 - NCT07047144RecruitingPhase 2
Apitegromab for infants with SMA under 2 years old
This study tests a new medicine called apitegromab for babies under 2 years old with spinal muscular atrophy (SMA). It looks at whether the drug can help with muscle strength and reaching motor milestones like sitting or rolling.
Phoenix, ArizonaAges Up to 2 years - NCT07001943Recruiting
Blood flow in stomach and gut injury in ICU patients
This trial checks if changes in blood flow to the stomach and intestines can predict gut injury in critically ill patients who need feeding through a tube. It uses a safe ultrasound test at the bedside.
Beijing, Beijing MunicipalityAges 18–80 - NCT06977269Recruiting
Brain stimulation safety study for spinal muscular atrophy
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
Kharkiv, Kharkiv OblastAges 12 years+ - NCT06955897Recruiting
Study of Fatigue in SMA Patients on Nusinersen
This study looks at how tired you feel during physical activities while being treated with nusinersen (Spinraza) for spinal muscular atrophy (SMA). The goal is to understand how well the treatment helps with daily energy levels.
New York, New YorkAges 12 years+ - NCT06888661Enrolling by invitationEarly Phase 1
Testing EXG001-307 for spinal muscular atrophy in infants
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
Shanghai, Shanghai MunicipalityAges 1 day–2 years - NCT05824169RecruitingPhase 1/Phase 2
Gene therapy for babies with severe spinal muscular atrophy
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
BeijingAges birth–6 months - NCT06421831RecruitingPhase 1/Phase 2
Gene therapy trial for spinal muscular atrophy type 3
This trial is testing a one-time gene therapy drug for people with SMA type 3. The goal is to see if it can safely improve muscle function and strength.
Beijing, Beijing MunicipalityAges 2 years+ - NCT06809387Enrolling by invitation
Magnetic brain stimulation for stuttering and reading in adults
This study tests whether a gentle magnetic stimulation technique called rTMS can help improve speech and reading fluency in adults who have stuttered since childhood. It aims to understand how a brain area involved in movement planning might play a role in stuttering.
IstanbulAges 18 years+ - NCT06772402Enrolling by invitation
Gene therapy for children with type 2 SMA
This trial tests a new gene therapy called GCB-001 for children with type 2 spinal muscular atrophy who can sit but not walk. It aims to improve muscle function and overall health.
Hangzhou, ZhejiangAges 2–12 - NCT06666816Recruiting
Watching changes in walking for muscle and nerve diseases
This study watches how people with certain muscle or nerve diseases walk over time. It may help doctors understand changes in walking patterns and is open to adults who can walk and have a genetic diagnosis of a neuromuscular condition.
Bosisio Parini, LeccoAges 18–75 - NCT06588803Enrolling by invitation
Long-term follow-up after EXG001-307 for type 1 SMA
This study follows up on patients with type 1 spinal muscular atrophy (SMA) who already received the EXG001-307 gene therapy in a previous trial. The goal is to monitor their long-term health and safety over time.
Shanghai, Shanghai MunicipalityAges 1 month+ - NCT06152302Recruiting
Water mobility test for infants with SMA
This study tests how well infants with spinal muscular atrophy (SMA) can move in water. The goal is to see if gentle water exercises can help with muscle weakness and overall development.
GarchesAges Up to 1 year - NCT05789758Recruiting
Study of Spinraza in pregnancy for 5q spinal muscular atrophy
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
Palo Alto, CaliforniaAges 18–54 - NCT05558566Recruiting
Neurofeedback training for Tourette-related tics in teens
This study tests whether brain training using “neurofeedback” can reduce Tourette syndrome tics in children ages 10–16. It compares an active neurofeedback condition to a control condition while measuring brain activity with an MRI.
New Haven, ConnecticutAges 10–16 - NCT05102916Recruiting
Registry for neuromuscular disorder patients in Switzerland
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
Aarau, Canton of AargauAges birth+
Hear when a new SMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sma?
- Yes. Clin2 currently lists 44 recruiting sma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.